Join
Live feed
·
PRReleasevia Quantisnow
Enanta Pharmaceuticals Inc. logo

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

ByQuantisnow·Wall Street's wire, on your screen.
ENTA· Enanta Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENTA (Enanta Pharmaceuticals Inc.) and more on Quantisnow.